- Home
- CANF vs ERNA Comparison
CANF vs ERNA Comparison
Compare CANF & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ERNA
- Stock Information
- Founded
- CANF 1994
- ERNA 2018
- Country
- CANF Israel
- ERNA United States
- Employees
- CANF N/A
- ERNA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- ERNA Health Care
- Exchange
- CANF Nasdaq
- ERNA Nasdaq
- Market Cap
- CANF 9.6M
- ERNA 10.2M
- IPO Year
- CANF N/A
- ERNA N/A
- Fundamental
- Price
- CANF $0.65
- ERNA $1.18
- Analyst Decision
- CANF Strong Buy
- ERNA
- Analyst Count
- CANF 2
- ERNA 0
- Target Price
- CANF $14.50
- ERNA N/A
- AVG Volume (30 Days)
- CANF 171.1K
- ERNA 89.5K
- Earning Date
- CANF 08-26-2025
- ERNA 11-11-2025
- Dividend Yield
- CANF N/A
- ERNA N/A
- EPS Growth
- CANF N/A
- ERNA N/A
- EPS
- CANF N/A
- ERNA N/A
- Revenue
- CANF $560,000.00
- ERNA $488,000.00
- Revenue This Year
- CANF $461.72
- ERNA N/A
- Revenue Next Year
- CANF N/A
- ERNA N/A
- P/E Ratio
- CANF N/A
- ERNA N/A
- Revenue Growth
- CANF N/A
- ERNA 201.24
- 52 Week Low
- CANF $0.63
- ERNA $1.17
- 52 Week High
- CANF $3.12
- ERNA $22.35
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- ERNA 35.05
- Support Level
- CANF $0.64
- ERNA $1.17
- Resistance Level
- CANF $0.68
- ERNA $1.57
- Average True Range (ATR)
- CANF 0.02
- ERNA 0.13
- MACD
- CANF 0.01
- ERNA 0.01
- Stochastic Oscillator
- CANF 41.25
- ERNA 2.50
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.